Form 4: IMMUNIC, INC. Director Vitt Acquires Stock Options

IMMUNIC, INC. reports that Director Daniel Vitt acquired 445,000 stock options on June 29, 2026, following stockholder approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan.

Summary

• Director Daniel Vitt acquired 445,000 stock options in IMMUNIC, INC. on June 29, 2026.
• The acquisition was made under a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c) affirmative defense conditions.
• These options are subject to the approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, which was obtained at the 2026 Annual Meeting of Stockholders.
• The underlying shares vest 25% on April 2, 2027, with the remainder vesting monthly over the subsequent 36 months.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard director stock option grant and plan amendment, indicating ongoing governance practices rather than significant new financial performance.

Positives

• Director acquisition of stock options indicates confidence in the company's future prospects.
• Stockholder approval of the equity incentive plan amendment suggests alignment between management and shareholders.
• The vesting schedule is structured to incentivize long-term commitment from the director.

Risks

• The options are conditional upon the approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, which was obtained at the 2026 Annual Meeting of Stockholders.
• The vesting schedule means the full benefit of the options is realized over a period of time, not immediately.

Future Outlook

The acquisition of stock options by a director, coupled with the approval of the equity incentive plan, suggests a positive outlook for the company, as it aligns the director's interests with long-term shareholder value.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, like IMMUNIC, INC., to attract and retain key talent and align their incentives with the company's performance and long-term growth.

Corporate Governance

Related Party Transactions

• Grant of 445,000 stock options to Director Daniel Vitt.

Stakeholder Impact

• Shareholders: The equity incentive plan amendment and director option grant are intended to align director interests with long-term shareholder value.
• Employees: The approved plan amendment may allow for future equity grants to other employees, potentially incentivizing performance.
• Management: Director Vitt's acquisition of options aligns his personal financial interests with the company's stock performance.

Next Steps

• Vesting of stock options over a 37-month period starting April 2, 2027.

Key Dates

Keywords

IMMUNIC, INC., IMUX, Form 4, Stock Options, Director, Equity Incentive Plan, Beneficial Ownership, SEC Filing